Table 1.

Designs of the included studies

EXCLAIM 2010MAGELLAN 2013APEX 2016MARINER 2018
Authors Hull et al15  Cohen et al14  Cohen et al16  Spyropoulos et al13  
Year of publication 2010 2013 2016 2018 
Setting International, multicenter International, multicenter International, multicenter International, multicenter 
Study design Randomized parallel placebo-controlled trial Randomized active comparator–controlled trial Randomized active comparator–controlled trial Randomized placebo-controlled trial 
Blinding Double blind Double blind Double blind, double dummy Double blind 
Cancer status Active cancer or history of cancer History of cancer or active cancer History of cancer or active cancer History of cancer in the past 5 y 
  Excludes intracranial neoplasm or metastasis Excludes intracranial neoplasm or metastasis Excludes intracranial neoplasm or metastasis, active lung cancer with residual disease, and nonmelanoma skin cancer Excludes all active cancers and nonmelanoma skin cancer 
Intervention 40 mg enoxaparin SC daily for 10 ± 4 d then enoxaparin 40 mg SC daily for additional 28 ± 4 d 10 mg rivaroxaban daily for 35 ± 4 d 80 mg betrixaban orally daily for 35-42 d (loading dose, 160 mg); reduced-dose betrixaban (40 mg) for patients with severe renal insufficiency or receiving concomitant P-glycoprotein inhibitor 10 mg rivaroxaban daily for 45 d after discharge 
Control 40 mg enoxaparin SC daily for 10 ± 4 d then placebo for additional 28 ± 4 d 40 mg enoxaparin SC daily for 10 ± 4 d 40 mg enoxaparin SC daily for 10 ± 4 d Placebo for 45 d after discharge 
EXCLAIM 2010MAGELLAN 2013APEX 2016MARINER 2018
Authors Hull et al15  Cohen et al14  Cohen et al16  Spyropoulos et al13  
Year of publication 2010 2013 2016 2018 
Setting International, multicenter International, multicenter International, multicenter International, multicenter 
Study design Randomized parallel placebo-controlled trial Randomized active comparator–controlled trial Randomized active comparator–controlled trial Randomized placebo-controlled trial 
Blinding Double blind Double blind Double blind, double dummy Double blind 
Cancer status Active cancer or history of cancer History of cancer or active cancer History of cancer or active cancer History of cancer in the past 5 y 
  Excludes intracranial neoplasm or metastasis Excludes intracranial neoplasm or metastasis Excludes intracranial neoplasm or metastasis, active lung cancer with residual disease, and nonmelanoma skin cancer Excludes all active cancers and nonmelanoma skin cancer 
Intervention 40 mg enoxaparin SC daily for 10 ± 4 d then enoxaparin 40 mg SC daily for additional 28 ± 4 d 10 mg rivaroxaban daily for 35 ± 4 d 80 mg betrixaban orally daily for 35-42 d (loading dose, 160 mg); reduced-dose betrixaban (40 mg) for patients with severe renal insufficiency or receiving concomitant P-glycoprotein inhibitor 10 mg rivaroxaban daily for 45 d after discharge 
Control 40 mg enoxaparin SC daily for 10 ± 4 d then placebo for additional 28 ± 4 d 40 mg enoxaparin SC daily for 10 ± 4 d 40 mg enoxaparin SC daily for 10 ± 4 d Placebo for 45 d after discharge 

SC, subcutaneous.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal